secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-088195
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%
--------------------------------------------------------------------------------

- Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.
- Cash, equivalents and marketable securities $462.6M, providing runway into first half of 2029.
- Initial Phase 1b data: MMR achieved in 47% (80 mg QD) and 69% (60/120 mg QD) of evaluable patients.
- Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected to initiate in second half of 2026.
- Rick Fair appointed CEO in December 2025; Scott Garland added to board in January 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/0001193125-26-088195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/elvn-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-088195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer